Lupin
Lupin Limited is an Indian pharmaceutical company engaged in the research, development, and global commercialization of branded and generic formulations. The company operates in key segments including generic pharmaceuticals, active pharmaceutical ingredients (APIs), and specialty therapeutics. Its product offerings span therapeutic categories such as anti-tuberculosis, respiratory, cardiovascular, diabetes, central nervous system, and anti-infective medications. Revenue is driven primarily by generic prescription drug sales across the United States, India, Europe, and emerging international markets. Lupin holds a major market position as one of the leading generic pharmaceutical companies based in India. The company is headquartered in Mumbai, India, and its shares are listed on the National Stock Exchange of India and BSE Limited.
21 of the funds FundTelligence covers report a position in Lupin.
- Legal name
- LUPIN
- Sector
- Health Care
- Country
- India
- Funds holding it
- 21
Funds holding Lupin
- BNP India Equity — BNP Paribas · 1.27 % (full portfolio disclosed, June 2026)
- SEB Emerging Marketsfond — SEB · 0.89 % (full portfolio disclosed, June 2026)
- SEB Asienfond ex Japan — SEB · 0.73 % (full portfolio disclosed, June 2026)
- Nordea Emerging Markets Sustainable Enhanced — Nordea Funds · 0.46 % (full portfolio disclosed, September 2026)
- Storebrand Emerging Markets Plus — Storebrand · 0.27 % (full portfolio disclosed, October 2026)
- Nordea Emerging Markets Enhanced — Nordea Funds · 0.21 % (full portfolio disclosed, September 2026)
- Danske Invest Global Emerging Markets Index Restricted — Danske Invest · 0.13 % (full portfolio disclosed, July 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.11 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 21 funds holding it.